Condition category
Respiratory
Date applied
25/04/2013
Date assigned
25/04/2013
Last edited
17/10/2016
Prospective/Retrospective
Prospectively registered
Overall trial status
Completed
Recruitment status
No longer recruiting

Plain English Summary

Background and study aims
Many people with asthma take regular inhaled steroids. These are either given alone or as part of a combination treatment. Despite regular treatment with inhaled steroids, some patients continue to have periods of poor asthma control, which are called exacerbations. Exacerbations often require treatment with steroid tablets and can lead to time away from school or work. Previous asthma guidelines have advised patients to double their dose of inhaled steroid at the first sign of a cold or worsening asthma symptoms, which has been shown not to work. A recent study has shown that increasing the dose to four times the normal dose for a short time may help in preventing an exacerbation but this is not certain. This study would like to test this by comparing a modified self-management plan to the one used in clinical care at the moment. This modified plan recommends taking four times the normal dose of inhaled corticosteroid when participant's asthma control starts to get worse.

Who can participate?
Men and women age 16 years of age and over who have asthma and have been prescribed an inhaled steroid.

What does the study involve?
If patients are interested in taking part, an appointment will be made for them to visit the clinic, where they can have a chat about the study and answer any questions. If patients are still interested in taking part they will need to sign a consent form and then some details will be recorded about them. Participants will also be asked to complete three short questionnaires and have their peak flow (maximum speed of expiration) measured. To find out which self-management plan is best and to avoid any bias, participants will not be able to choose which plan they receive, instead they will be allocated one of the two plans (asthma self-management plan which includes an increase in inhaled corticosteroid or the same plan without an increase in inhaled corticosteroid) by chance. The self-management plan will advise participants what to do if their asthma gets worse. Participants will also receive a diary card and training about how and when to complete this. At some sites, participants may be asked if they can attach an electronic device to one of their inhalers to count how many puffs of the inhaler they take. Participants will need to come back to the clinic at 6 and 12 months after they start the study. During these visits the study team will review and discuss their asthma self-management plan and participants will be asked to complete several short questionnaires asking about their quality of life and use of NHS services. This should take no longer than 45 minutes. In addition, if the participant's asthma starts to get worse during the study and they move into Zone 2 of their self-management plan, participants will need to start to complete the diary card and to make an appointment to come into the clinic 14 days later. At this visit a member of the research team will review their diary card and discuss their asthma self-management plan. Participants will also be asked to complete a short quality of life questionnaire. The research team will send text message to the participants every month just to remind them about their self-management plan. Participants will remain on their own regular asthma medication throughout the study as part of their self-management plan.

What are the possible benefits and risks of participating?
If the participants do not usually use a self-management plan their asthma control may improve during the study. There is a chance that they may develop oral thrush or a hoarse voice if their self-management plan recommends extra inhaled steroid. The risk of this can be reduced by rinsing their mouth after using their steroid inhaler and it usually resolves spontaneously once the dose is reduced again. If not it is easily treated with antifungal throat lozenges or liquid prescribed by their doctor

Where is the study run from?
Nottingham Clinical Trials Unit (UK)

When is the study starting and how long is it expected to run for?
Enrolment commenced in May 2013 with a recruitment period of 24 months with a total study duration of 42 (each participant is enrolled for 12 months duration).

Who is funding the study?
NIHR Health Technology Assessment Programme

Who is the main contact?
Andrew Skeggs
andrew.skeggs@nottingham.ac.uk

Trial website

Contact information

Type

Scientific

Primary contact

Mr Andrew Skeggs

ORCID ID

Contact details

Nottingham Clinical Trials Unit
Nottingham Health Science Partners
Queen's Medical Centre
Derby Road
Nottinghamshire
Nottingham
NG7 2UH
United Kingdom
+44 (0)115 8844949
andrew.skeggs@nottingham.ac.uk

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

14257; HTA 10/143/01

Study information

Scientific title

The clinical and cost effectiveness of temporarily quadrupling the dose of inhaled steroid to prevent asthma exacerbations: a pragmatic, randomised, normal care-controlled clinical trial

Acronym

FAST

Study hypothesis

Determine whether the proposed asthma self-management plan reduces asthma exacerbations requiring oral steroids or unscheduled healthcare consultation for asthma.

More details can be found at: http://www.nets.nihr.ac.uk/projects/hta/1014301
Protocol can be found at: http://www.nets.nihr.ac.uk/__data/assets/pdf_file/0015/81141/PRO-10-143-01.pdf

Ethics approval

NRES Committee North West - Greater Manchester South, 24/04/2013, ref: 13/NW/0184

Study design

Multi-centre pragmatic randomised normal care-controlled clinical trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Trial setting

GP practices

Trial type

Treatment

Patient information sheet

Not available in web format, please use the contact details to request a patient information sheet

Condition

Respiratory (asthma)

Intervention

Participants will be randomised to either an asthma self-management plan which includes an increase in inhaled corticosteroid or the same plan without an increase in inhaled corticosteroid.

Intervention type

Drug

Phase

Not Applicable

Drug names

Primary outcome measures

Time to first asthma exacerbation, defined as: the need for systemic corticosteroids and/or unscheduled health care consultation for asthma.

Secondary outcome measures

1. Number of participants who exacerbate, defined as: the need for systemic corticosteroids and/or unscheduled health care consultation for asthma (i.e. reaching zone 3 or 4 of the Asthma UK self-management plan).
2. Total number of exacerbations, defined as: the need for systemic corticosteroids and/or unscheduled health care consultation for asthma (i.e. reaching zone 3 or 4 of the Asthma UK self-management plan).
3. The number of participants using systemic corticosteroids for an acute exacerbation of asthma.
4. The number of participants requiring unscheduled healthcare consultation for asthma.
5. The total number of courses of systemic corticosteroids for an acute exacerbation of asthma.
6. The total number of unscheduled healthcare consultations for asthma.
7. The time to participants requiring systemic corticosteroids for an acute exacerbation of asthma.
8. The time to unscheduled healthcare consultation for asthma
9. The area under the morning peak flow curve over 2 weeks from the point of activating stage 2 of the asthma plan.
10. Change in Asthma Control Questionnaire 2 weeks after activating stage 2 of the self-management plan.
11. Cumulative dose of inhaled and systemic steroids used in the 12 months after randomisation.
12. Cost and resource audits of both trial arms will be reported as incremental cost per asthma exacerbation prevented and cost per quality adjusted life year gained (QALY).

Overall trial start date

01/05/2013

Overall trial end date

31/08/2016

Reason abandoned

Eligibility

Participant inclusion criteria

1. Male or female aged 16 years and over
2. Clinician diagnosed asthma treated with a licensed dose of inhaled corticosteroid (i.e. step 2 to 4 of the British Thoracic Society [BTS] /Scottish Intercollegiate Guidelines Network [SIGN] guidelines).
3. One or more exacerbation in the last 12 months requiring treatment with systemic corticosteroids.

Participant type

Patient

Age group

Adult

Gender

Both

Target number of participants

1773

Participant exclusion criteria

Potential participants will be excluded on the basis of:
1. History more in keeping with smoking related chronic obstructive pulmonary disease [COPD] (smoked > 20 pack years, without evidence of significant reversibility and eosinophilia).
2. On maintenance oral steroids (i.e. step 5 BTS/SIGN guidelines).
3. Using a combination inhaler for both maintenance and relief treatment.
4. Experienced an exacerbation within 4 weeks of randomisation
5. Pregnant women, lactating women or women who are planning to become pregnant

Recruitment start date

01/05/2013

Recruitment end date

31/01/2016

Locations

Countries of recruitment

United Kingdom

Trial participating centre

Nottingham University Hospitals
Nottingham
NG7 2UH
United Kingdom

Trial participating centre

King’s Mill Hospital
Sutton-in-Ashfield
NG17 4JL
United Kingdom

Trial participating centre

Glenfield Hospital
Leicester
LE3 9QP
United Kingdom

Trial participating centre

Aintree University Hospital
Liverpool
L9 7AL
United Kingdom

Trial participating centre

Royal Liverpool and Broadgreen hospital
Liverpool
L7 8XP
United Kingdom

Trial participating centre

Freeman Hospital
Newcastle
NE7 7DN
United Kingdom

Trial participating centre

Aberdeen Royal Infirmary
Aberdeen
AB25 2ZN
United Kingdom

Trial participating centre

Arrowe Park Hospital
Liverpool
CH49 5PE
United Kingdom

Trial participating centre

Blackpool Victoria Hospital
Blackpool
FY3 8NR
United Kingdom

Trial participating centre

University Hospital of South Manchester
Manchester
M23 9LT
United Kingdom

Trial participating centre

GP practices in the following CRNs:
East Midlands, Wessex, Eastern, North West Coast, North East & Cumbria, Greater Manchester, West Midlands (South), West of England, Kent, Surrey & Sussex
-
United Kingdom

Sponsor information

Organisation

University of Nottingham (UK)

Sponsor details

c/o Angela Shone
Research Innovation Services
King's Meadow Campus
Lenton Lane
Nottingham
NG7 2NR
United Kingdom

Sponsor type

University/education

Website

http://www.nottingham.ac.uk/

Funders

Funder type

Government

Funder name

Health Technology Assessment Programme

Alternative name(s)

NIHR Health Technology Assessment Programme, HTA

Funding Body Type

government organisation

Funding Body Subtype

Federal/National Government

Location

United Kingdom

Results and Publications

Publication and dissemination plan

To be confirmed at a later date

Intention to publish date

01/03/2017

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

2016 protocol in: https://www.ncbi.nlm.nih.gov/pubmed/27737713

Publication citations

Additional files

Editorial Notes

17/10/2016: Publication reference added. 23/06/2015: The target number of participants was changed from 2300 to 1773.